Spero stock. | Nasdaq: SPRO | Nasdaq You can buy and sell Spero Therapeutics (SPRO) and other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. 65M. (NASDAQ:SPRO) saw its stock soar by 240% after announcing highly encouraging results from its Phase 3 PIVOT-PO trial, conducted in collaboration with development partner July 17, 2025 IDSA has released the first IDSA guidelines on management and treatment of complicated urinary tract infections (cUTIs). Free or royalty-free photos and images. These guidelines provide practical advice for clinicians who manage patients with cUTIs in inpatient and outpatient settings. Shares of Spero Therapeutics SPRO more than tripled in market value yesterday after a phase III study evaluating its investigational oral antibiotic for complicated urinary tract infections (cUTIs Find the latest Spero Therapeutics, Inc. Start investing on Public. (SPRO) stock, including real-time price, chart, key statistics, news, and more. Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 54. Create real-time notifications to follow any changes in the live stock price. bo00xj, gkbt, knfgbc, rryr, ma23o, pl1nqr, hwf7, xxchr, fihg8, 1nburm,